Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of glycopyrronium bromide + neostigmine injection for reversal of residual non-depolarizing neuromuscular blockade after general anesthesia
CTR20250232Phase 3Completed
- Sponsor
- Fenghua Pharma
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of neostigmine + glycopyrrolate in neuromuscular block (NMB), sponsored by Fenghua Pharma. Started Jan 2025; status: completed.
02
Drugs
neostigmine + glycopyrrolate
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on CTR20250232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250232.